 |
 |
 |
 |
 |
 |
 |
 |
PorTfolio of investments
Achillion Pharmaceuticals, Inc.
Achillion (Nasdaq: ACHN) is a biopharmaceutical company focused on the discovery, development, and commercialization of novel, small molecule inhibitors targeting infectious disease. Pipeline programs include a first-in-class HCV replicase inhibitor partnered with Gilead and an HCV protease inhibitor. Additional drug candidates target treatment of HIV and bacterial infections.
» Achillion Website
Aerovance, Inc. is focused on the development and commercialization of biologics for respiratory and inflammatory diseases. The company has several clinical development programs in progress around two novel compounds, an IL4/13 receptor antagonist and a serine protease inhibitor. In May 2006 Aerovance secured $60 million in a financing led by Clarus Ventures.
» Aerovance Website
Avanir Pharmaceuticals (Nasdaq:AVNR) is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. Avanir’s products and product candidates address therapeutic markets that include central nervous system disorders, inflammation, and infectious disease. Zenvia™ is Avanir's lead product candidate for the treatment of pseudobulbar affect (PBA), also known as involuntary emotional expression disorder (IEED).
» Avanir Website
Biolex is a clinical-stage biopharmaceutical company that develops hard-to-make therapeutic proteins and optimizes monoclonal antibodies in a proprietary plant-based expression system. The company’s product candidates target superior efficacy/tolerability profiles and address large, proven pharmaceutical markets. Biolex’s lead product candidate, Locteron®, a once-every-two-week controlled release formulation of interferon alpha, is in Phase 2 clinical testing for the treatment of chronic hepatitis C.
» Biolex Website
CoMentis, Inc. is engaged in the discovery and development of small-molecule drugs to treat neurovascular disease indications, such as Alzheimer’s disease, AMD and cognitive disorders. The company has two fundamental technology platforms: (i) beta-secretase inhibitors for the treatment of Alzheimer’s disease; and (ii) nACh receptor agonists and antagonists for the treatment of angiogenesis mediated diseases and cognitive disorders.
» CoMentis Website
Privately-held ESBATech AG is a Zurich, Switzerland based drug discovery and development company focused on advancing antibody fragments for therapeutic applications.
» ESBATech Website
FerroKin Biosciences, Inc. FerroKin Biosciences Inc., a San Carlos, Calif.-based company, is developing an iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. Clarus Ventures has co-invested with Burrill & Co. and Celgene Inc.
Globus Medical, Inc. Globus Medical, Inc. is focused on the development of products that enable spine surgeons to employ both fusion and non-fusion solutions to promote healing in patients with spinal disorders. Today Globus is one of the fastest growing spinal implant companies in the world and a recognized leader in the development of motion sparing technology.
» Globus Medical Website
Heptares Therapeutics, Ltd. Heptares is a drug discovery company focused on the discovery of novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs). The Company is deploying its proprietary StaR™ technology principally against highly validated but currently difficult or intractable GPCR targets in several disease areas.
» Heptares Website
InSet Technologies is focused on developing better treatment options for the 75 million Americans in chronic pain, more than diabetes, heart disease, and cancer combined. Our first product for delivery of intrathecal medication, the Prometra® programmable implantable pump, is undergoing clinical trials. InSet is headquartered in Mount Olive, NJ.
» Inset Website
Link Medicine, Inc. Link Medicine is advancing disease-modifying technologies targeted at Alzheimer's, Parkinson's and other neurodegenerative diseases where current symptomatic therapies are limited in efficacy or duration, and at orphan indications which lack any meaningful symptomatic treatments.
» Link Medicine Website
Lycera Corporation Lycera is an early stage biotechnology company developing first in class small molecule drugs for the treatment of autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease. Lycera’s pipeline includes proprietary small molecules against two novel targets, a mitochondrial molecule that is central to lymphocyte bioenergetics and a nuclear hormone receptor that modulates the Th17 pathway. Lycera’s small molecule drugs have the potential for best in class oral efficacy without the adverse effects of current immunosuppressive agents.
» Lycera Corporation Website
NanoString Technologies, Inc.Nanostring is a commercial stage company and an emerging leader in the expression profiling market. Its lead product is the only system capable of highly multiplexed direct quantification of individual mRNAs in a biological sample without the use of enzymes or amplification. With sensitivity below a single copy of mRNA per cell, high accuracy, robust output, and simplified workflow, the Nanostring platform offers investigators the benefits of the accuracy of PCR with the ability to interrogate more genes (up to a thousand) that would traditionally not be possible with PCR . Unlike PCR or microarrays, the Nanostring technology affords digital results by directly imaging and counting mRNAs on solid support.
» NanoString Technologies Website
Neomend, Inc.Neomend, Inc. based in Irvine, CA has developed advanced surgical sealant, adhesion barrier, and applicator technologies based on its proprietary protein and polymer based hydrogel platform. Targeted surgical procedures include thoracic, spine, gynecology and general surgery. The company's initial product, ProGELTM Pleural Air Leak Sealant, has received FDA PMA approval and is the only indicated surgical sealant in the U.S. for sealing lung air leaks in thoracic surgery. ProGEL showed statistically significant reductions in intra-operative air leaks and length of hospital stay days in the PMA trial.
» Neomend Website
Ophthotech Corp.Ophthotech Corporation is a privately-held, clinical-stage biotechnology company focused on developing and commercializing therapies for both wet and dry Age-Related Macular Degeneration (AMD). Three new molecular entities are currently in clinical development: E10030, an anti-platelet-derived growth factor (PDGF) pegylated aptamer; ARC1905, a pegylated aptamer targeting the C5 component of the complement cascade; and Volociximab, a monoclonal antibody targeting the transmembrane receptor α5β1 integrin. All three Ophthotech drug products are currently in a phase 1 clinical trial for combination treatment with anti-VEGF therapy (Lucentis®). The most advanced product, E10030, has completed a Phase 1 trial.
» Ophthotech Website
Oxford Immunotec Ltd develops and sells clinical diagnostic products based on its patented, regulatory approved T-SPOT® technology. T-SPOT is a novel platform technology that opens up new ways of diagnosing and monitoring infections by providing a simple and extremely accurate method of studying a person’s cellular immune response to an infection. Oxford Immunotec’s first product T-SPOT®.TB, is a revolutionary new blood test for diagnosing Tuberculosis infection, offering unmatched sensitivity.
» Oxford Immunotec Website
Pearl Therapeutics, Inc. Pearl Therapeutics, Inc. is a privately-held company focused on improving the treatment and prevention of widely prevalent respiratory disorders. Pearl has licensed a suite of particle technologies from Nektar Therapeutics, Inc. to rapidly advance their product candidates through development.
Pelikan Technologies is dedicated to the development of innovative hand-held diagnostic and monitoring devices capable of significantly improving the screening and management of a variety of medical conditions. In addition to diabetes, the company's versatile technology platform has applications across a range of other medical conditions that involve blood screening and monitoring. Point-of-care testing and diagnostic panel test systems also represent markets that can benefit from Pelikan's novel technology.
» Pelikan Website
Proacta, Inc. Proacta is a private, clinical-stage biotechnology company focused on developing a new generation of hypoxia-activated prodrug compounds to treat cancer. These compounds are designed to improve outcomes of current cancer treatment regimens with a broader tumor killing effect. Proacta’s lead compound is selectively activated in hypoxic regions of solid tumors and can diffuse locally within the tumor to kill non-hypoxic cells. In January 2007, Proacta secured a $35 million Series B financing led by Clarus Ventures.
» Proacta Website
SARcode, Inc. SARcode is a private, San Francisco based company focused on the development of small molecule LFA-1 inhibitors to treat inflammatory diseases. In December, 2006 SARcode secured $25 million in a financing co-led by Clarus Ventures and Alta Partners.
» SARcode Website
Sientra, Inc. Sientra is a private medical device company focused on developing and marketing a broad portfolio of products within the rapidly growing plastic surgery and aesthetics market. In April 2007, Sientra secured $85 million in a Series B financing co-led by Clarus Ventures.
» Sientra Website
Taligen is a biopharmaceutical company focused on developing inhibitors of the complement system for a variety of therapeutic indications. Clarus co-led the Series B financing of the company in January 2008.
» Taligen Website
TyRx, Inc. TyRx develops and commercializes proprietary, polymer-based, antibiotic-eluting medical products that prevent infection and capsular scar formation, two common morbidities associated with medical device implants.It currently has 3 FDA approved products including AIGIS CRMD, an antibiotic-eluting mesh envelope to prevent infections associated with the implantation of cardiac rhythm management devices (CRMDs) such as pacemakers and implantable defibrillators. The company launched AIGIS CRMD in the US in Q3 2008 with its own specialty sales force.
» TyRx Website
Variation Biotechnologies, Inc.
Variation Biotechnologies Inc. is focused on the development and commercialization of novel peptide-based vaccines for infectious diseases. The company has several preclinical vaccine development programs in progress for seasonal influenza, pandemic influenza, and HIV. In December 2006, Variation secured $36 million in a financing led by Clarus Ventures.
» Variation Website
Virdante Pharmaceuticals, Inc.
Virdante Pharmaceuticals is developing safer and more effective drugs for autoimmune and inflammatory diseases. Our products incorporate a proprietary “sialic switch” technology to improve the anti-inflammatory properties of antibodies.
» Virdante Website
Zogenix, Inc. Zogenix, Inc. is a specialty pharmaceutical company focused on the development and commercialization of medicines to treat CNS disorders and pain. Zogenix’ initial focus is the late-stage development and commercialization of Intraject® sumatriptan -- a needle-free, single-use, disposable, subcutaneous delivery system that will compete in the $2.5 billion triptan segment of the migraine market. In August, 2006, Zogenix secured $60 million in a financing co-led by Clarus Ventures.
» Zogenix Website